---
title: "Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration: Safety questions"
description: "Safety questions on Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects and Warnings. Questions: What side effects did Vabysmo cause in wet AMD trials? How common are cataracts with Vabysmo in wet AMD trials? Can Vabysmo cause retinal pigment epithelial tears in wet AMD? How common is eye inflammation with Vabysmo in wet AMD trials? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration: Safety questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Vabysmo](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf)

Safety questions that apply to every indication of Vabysmo are on [Vabysmo (faricimab-svoa), all indications: Safety](https://www.evicenter.com/medical-information/vabysmo/safety).

## Side effects

<a id="vabysmo-namd-side-effects"></a>

### What side effects did Vabysmo cause in wet AMD trials?

> “Table 1: Common Adverse Reactions (≥ 1%)”

Source: [VABYSMO: Prescribing information, page 12, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=12)

> “Adverse Reactions 
>
> VABYSMO 
> Active Control (aflibercept)  
> AMD 
> N=664 
> DME 
> N=1,262 
> RVO 
> N=641 
> AMD 
> N=662 
> DME 
> N=625 
> RVO 
> N=635 
> Cataract 
> 3% 
> 15% 
> < 1% 
> 2% 
> 12% 
> 1% 
> Conjunctival hemorrhage 
> 7% 
> 8% 
> 3% 
> 8% 
> 7% 
> 4% 
> Vitreous detachment 
> 3% 
> 5% 
> 2% 
> 3% 
> 4% 
> 2% 
> Vitreous floaters  
> 3% 
> 4% 
> 2% 
> 2% 
> 3% 
> 2% 
> Retinal pigment epithelial tear<sup>a</sup> 
> 3% 
>
>
> 1% 
>
>
> Intraocular pressure increased 
> 3% 
> 4% 
> 1% 
> 2% 
> 3% 
> 3% 
> Eye pain 
> 3% 
> 3% 
> < 1% 
> 3% 
> 3% 
> < 1% 
> Intraocular inflammation<sup>b</sup> 
> 2% 
> 1% 
> 1% 
> 1% 
> 1% 
> < 1% 
> Eye irritation 
> 1% 
> < 1% 
> < 1% 
> < 1% 
> 1% 
> < 1% 
> Lacrimation increased 
> 1% 
> 1% 
> 0 
> 1% 
> < 1% 
> < 1% 
> Ocular discomfort 
> 1% 
> 1% 
> < 1% 
> < 1% 
>  < 1% 
> < 1% 
> <sup>a</sup> AMD only 
> <sup>b</sup> Including iridocyclitis, iritis, uveitis, vitritis”

Source: [VABYSMO: Prescribing information, page 12, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=12)

Note: Table 1 columns are VABYSMO in AMD (N=664), DME (N=1,262), and RVO (N=641), then aflibercept in AMD (N=662), DME (N=625), and RVO (N=635), in that order; the AMD columns are the wet AMD trials (TENAYA and LUCERNE).

<a id="vabysmo-cataract"></a>

### How common are cataracts with Vabysmo in wet AMD trials?

> “Cataract 
> 3% 
> 15% 
> < 1% 
> 2% 
> 12% 
> 1%”

Source: [VABYSMO: Prescribing information, page 12, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=12)

Note: In this row of Table 1, the first value is VABYSMO in AMD (N=664) and the fourth is aflibercept in AMD (N=662); the other values are from the DME and RVO trials.

<a id="vabysmo-rpe-tear"></a>

### Can Vabysmo cause retinal pigment epithelial tears in wet AMD?

> “Retinal pigment epithelial tear<sup>a</sup> 
> 3% 
>
>
> 1%”

Source: [VABYSMO: Prescribing information, page 12, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=12)

> “<sup>a</sup> AMD only”

Source: [VABYSMO: Prescribing information, page 12, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=12)

Note: In this row of Table 1, the first value is VABYSMO in AMD (N=664) and the second is aflibercept in AMD (N=662).

<a id="vabysmo-intraocular-inflammation"></a>

### How common is eye inflammation with Vabysmo in wet AMD trials?

> “Intraocular inflammation<sup>b</sup> 
> 2% 
> 1% 
> 1% 
> 1% 
> 1% 
> < 1%”

Source: [VABYSMO: Prescribing information, page 12, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=12)

> “<sup>b</sup> Including iridocyclitis, iritis, uveitis, vitritis”

Source: [VABYSMO: Prescribing information, page 12, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=12)

> “VABYSMO is contraindicated in patients with active intraocular inflammation.”

Source: [VABYSMO: Prescribing information, page 10, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=10)

Note: In the Table 1 row, the first value is VABYSMO in AMD (N=664) and the fourth is aflibercept in AMD (N=662); the other values are from the DME and RVO trials.

## Warnings

<a id="vabysmo-namd-stroke-heart-attack"></a>

### Does Vabysmo raise stroke or heart attack risk in wet AMD?

> “Although there was a low rate of arterial thromboembolic events (ATEs) observed in the 
> VABYSMO clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF 
> inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death 
> (including deaths of unknown cause).”

Source: [VABYSMO: Prescribing information, page 11, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=11)

> “The incidence of reported ATEs in the nAMD studies during the first year was 1% (7 out of 664) 
> in patients treated with VABYSMO compared with 1% (6 out of 662) in patients treated with 
> aflibercept [see Clinical Studies (14.1)].”

Source: [VABYSMO: Prescribing information, page 11, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=11)

## Related pages
- [Medical information: Vabysmo (faricimab-svoa): Neovascular age-related macular degeneration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration)
- [Indication](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/clinical-trials)
- [Dosing and administration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/dosing-and-administration)
